top of page
検索

FDA approves Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer

執筆者の写真: nuaxia
nuaxia
10月27日
読了時間: 2分

The FDA has approved Pfizer's Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer, expanding the combination into an earlier treatment setting.


The approval authorises Talzenna (talazoparib) with Xtandi (enzalutamide) for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer whose tumours harbour homologous recombination repair gene mutations identified using an FDA-authorised test.


The decision was supported by the Phase III TALAPRO-3 study involving 599 patients and extends the combination's use beyond its previously authorised metastatic castration-resistant prostate cancer indication.

Field

Content

Article Type

Approvals

Regulatory Authority

U.S. Food and Drug Administration

Regulatory Decision

New indication approval

Approval Date

26 October 2026

Company

Pfizer

Approved Combination

Talzenna plus Xtandi

Active Ingredients

Talazoparib; enzalutamide

Drug Classes

PARP inhibitor; androgen receptor inhibitor

Therapeutic Area

Oncology; prostate cancer

Approved Indication

Metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations

Patient Population

Adults with eligible HRR-mutated metastatic prostate cancer

Biomarker

Homologous recombination repair gene mutations

Biomarker Testing

FDA-authorised test

Supporting Clinical Study

Phase III TALAPRO-3

Study Enrollment

599 patients

Efficacy Results

Specific efficacy estimates not provided in supplied summary

Previous Approved Setting

Metastatic castration-resistant prostate cancer

New Treatment Setting

Earlier metastatic androgen pathway modulation-naïve or -sensitive disease

Geography

United States

What Happened

The FDA approved talazoparib with enzalutamide for adults with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.

Why It Matters

The approval expands access to a biomarker-directed PARP inhibitor combination earlier in the metastatic prostate cancer treatment pathway.

Clinical Evidence

The Phase III TALAPRO-3 study enrolled 599 patients; detailed efficacy outcomes were not included in the supplied summary.

Key Takeaway

Talzenna plus Xtandi now has an additional US indication for selected HRR-mutated metastatic prostate cancers beyond the castration-resistant setting.

What to Watch

Updated prescribing information, biomarker testing uptake, clinical guideline integration, reimbursement and real-world outcomes.

Primary Source

U.S. Food and Drug Administration

Primary Source URL

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive

Relevant Date

26 October 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

コメント

5つ星のうち0と評価されています。
まだ評価がありません

評価を追加
bottom of page